对致敏性食品污染物的反应性:对市场上产品的研究。

IF 4.6 2区 医学 Q2 ALLERGY
Alessandro Fiocchi, Linda Monaci, Elisabetta De Angelis, Veronica Calandrelli, Lamia Dahdah, Rocco Valluzzi, Sara Urbani, Carmen Mazzuca, Stefania Arasi, Arianna Cafarotti, Carla Riccardi, Maria Cristina Artesani, Lorenza Putignani, Valentina Pecora, Valeria Marzano, Vincenzo Fierro
{"title":"对致敏性食品污染物的反应性:对市场上产品的研究。","authors":"Alessandro Fiocchi,&nbsp;Linda Monaci,&nbsp;Elisabetta De Angelis,&nbsp;Veronica Calandrelli,&nbsp;Lamia Dahdah,&nbsp;Rocco Valluzzi,&nbsp;Sara Urbani,&nbsp;Carmen Mazzuca,&nbsp;Stefania Arasi,&nbsp;Arianna Cafarotti,&nbsp;Carla Riccardi,&nbsp;Maria Cristina Artesani,&nbsp;Lorenza Putignani,&nbsp;Valentina Pecora,&nbsp;Valeria Marzano,&nbsp;Vincenzo Fierro","doi":"10.1002/clt2.12301","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>The frequency and severity of reactions in food-allergic consumers exposed to unintentional food allergen contamination during production is unknown. To warn allergic consumers, it has been suggested for pre-packaged foods to be precautionary labelled when the food allergen contamination may exceed the amount to which 1%–5% of the population could react (ED01–ED05). ED01 for hazelnut and milk have been estimated at 0.1 and 0.2 mg, respectively, by the Voluntary Incidental Trace Allergen Labelling (VITAL) initiative. The respective reference doses recommended by the FAO/WHO Codex consultation are 3 and 2 mg. We evaluated the reactivity to potential traces of milk and hazelnut allergens in allergen-free pre-packaged products by children affected by severe allergies to milk and hazelnuts.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Oral Food Challenges with commercially available hazelnut-free wafer biscuits and milk-free chocolate pralines were administered to patients with severe food allergies to hazelnut and cow's milk, respectively. Contamination levels of milk or hazelnut allergens were measured using chromatographic separation interfaced with triple quadrupole mass spectrometry.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>No hazelnut allergic patient showed allergic reactions to exposure to biscuits, nor any milk allergic patient displayed allergic reactions to the dark chocolate praline. While no hazelnut trace was detected in biscuits, the praline was found to be contaminated by milk at concentrations ranging between 8 and 35 mg total protein/kg food. In our dose model, these amounts exceeded 1.5–10 times the VITAL ED01 and reached the threshold suggested by the FAO/WHO Codex consultation.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Upon the consumption of food products available on the market, many patients with severe food allergies tolerate significantly higher doses of allergen than reference doses indicated in the VITAL system used for precautionary allergen labelling. These doses support the safety of the FAO/WHO recommended reference doses.</p>\n </section>\n </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"13 9","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2023-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12301","citationCount":"0","resultStr":"{\"title\":\"Reactivity to allergenic food contaminants: A study on products on the market\",\"authors\":\"Alessandro Fiocchi,&nbsp;Linda Monaci,&nbsp;Elisabetta De Angelis,&nbsp;Veronica Calandrelli,&nbsp;Lamia Dahdah,&nbsp;Rocco Valluzzi,&nbsp;Sara Urbani,&nbsp;Carmen Mazzuca,&nbsp;Stefania Arasi,&nbsp;Arianna Cafarotti,&nbsp;Carla Riccardi,&nbsp;Maria Cristina Artesani,&nbsp;Lorenza Putignani,&nbsp;Valentina Pecora,&nbsp;Valeria Marzano,&nbsp;Vincenzo Fierro\",\"doi\":\"10.1002/clt2.12301\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>The frequency and severity of reactions in food-allergic consumers exposed to unintentional food allergen contamination during production is unknown. To warn allergic consumers, it has been suggested for pre-packaged foods to be precautionary labelled when the food allergen contamination may exceed the amount to which 1%–5% of the population could react (ED01–ED05). ED01 for hazelnut and milk have been estimated at 0.1 and 0.2 mg, respectively, by the Voluntary Incidental Trace Allergen Labelling (VITAL) initiative. The respective reference doses recommended by the FAO/WHO Codex consultation are 3 and 2 mg. We evaluated the reactivity to potential traces of milk and hazelnut allergens in allergen-free pre-packaged products by children affected by severe allergies to milk and hazelnuts.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Oral Food Challenges with commercially available hazelnut-free wafer biscuits and milk-free chocolate pralines were administered to patients with severe food allergies to hazelnut and cow's milk, respectively. Contamination levels of milk or hazelnut allergens were measured using chromatographic separation interfaced with triple quadrupole mass spectrometry.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>No hazelnut allergic patient showed allergic reactions to exposure to biscuits, nor any milk allergic patient displayed allergic reactions to the dark chocolate praline. While no hazelnut trace was detected in biscuits, the praline was found to be contaminated by milk at concentrations ranging between 8 and 35 mg total protein/kg food. In our dose model, these amounts exceeded 1.5–10 times the VITAL ED01 and reached the threshold suggested by the FAO/WHO Codex consultation.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>Upon the consumption of food products available on the market, many patients with severe food allergies tolerate significantly higher doses of allergen than reference doses indicated in the VITAL system used for precautionary allergen labelling. These doses support the safety of the FAO/WHO recommended reference doses.</p>\\n </section>\\n </div>\",\"PeriodicalId\":10334,\"journal\":{\"name\":\"Clinical and Translational Allergy\",\"volume\":\"13 9\",\"pages\":\"\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2023-09-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12301\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Translational Allergy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/clt2.12301\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Allergy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/clt2.12301","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:食品过敏消费者在生产过程中暴露于非故意的食品过敏原污染,其反应的频率和严重程度尚不清楚。为了警告过敏消费者,有人建议,当食品过敏原污染可能超过1%-5%人群的反应量时,预包装食品应贴上预防性标签(ED01-ED05)。自愿附带微量过敏原标签(VITAL)倡议估计榛子和牛奶的ED01分别为0.1和0.2 mg。粮农组织/世界卫生组织法典咨询建议的参考剂量分别为3和2毫克。我们评估了受牛奶和榛子严重过敏影响的儿童对无过敏原预包装产品中潜在微量牛奶和榛子过敏原的反应性。方法:对榛子和牛奶严重食物过敏的患者分别使用市售的无榛子威化饼干和无牛奶巧克力果仁糖进行口服食物挑战。牛奶或榛子过敏原的污染水平是使用色谱分离与三重四极杆质谱联用来测量的。结果:没有榛子过敏患者对饼干过敏,也没有牛奶过敏患者对黑巧克力果仁糖过敏。虽然在饼干中没有检测到榛子的痕迹,但发现果仁糖被牛奶污染,牛奶的总蛋白质浓度在8至35毫克/公斤食物之间。在我们的剂量模型中,这些数量超过了VITAL ED01的1.5-10倍,并达到了粮农组织/世界卫生组织法典咨询建议的阈值。结论:在食用市场上可用的食品后,许多严重食物过敏的患者耐受的过敏原剂量明显高于VITAL系统中用于预防性过敏原标签的参考剂量。这些剂量支持粮农组织/世界卫生组织推荐参考剂量的安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Reactivity to allergenic food contaminants: A study on products on the market

Reactivity to allergenic food contaminants: A study on products on the market

Background

The frequency and severity of reactions in food-allergic consumers exposed to unintentional food allergen contamination during production is unknown. To warn allergic consumers, it has been suggested for pre-packaged foods to be precautionary labelled when the food allergen contamination may exceed the amount to which 1%–5% of the population could react (ED01–ED05). ED01 for hazelnut and milk have been estimated at 0.1 and 0.2 mg, respectively, by the Voluntary Incidental Trace Allergen Labelling (VITAL) initiative. The respective reference doses recommended by the FAO/WHO Codex consultation are 3 and 2 mg. We evaluated the reactivity to potential traces of milk and hazelnut allergens in allergen-free pre-packaged products by children affected by severe allergies to milk and hazelnuts.

Methods

Oral Food Challenges with commercially available hazelnut-free wafer biscuits and milk-free chocolate pralines were administered to patients with severe food allergies to hazelnut and cow's milk, respectively. Contamination levels of milk or hazelnut allergens were measured using chromatographic separation interfaced with triple quadrupole mass spectrometry.

Results

No hazelnut allergic patient showed allergic reactions to exposure to biscuits, nor any milk allergic patient displayed allergic reactions to the dark chocolate praline. While no hazelnut trace was detected in biscuits, the praline was found to be contaminated by milk at concentrations ranging between 8 and 35 mg total protein/kg food. In our dose model, these amounts exceeded 1.5–10 times the VITAL ED01 and reached the threshold suggested by the FAO/WHO Codex consultation.

Conclusions

Upon the consumption of food products available on the market, many patients with severe food allergies tolerate significantly higher doses of allergen than reference doses indicated in the VITAL system used for precautionary allergen labelling. These doses support the safety of the FAO/WHO recommended reference doses.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinical and Translational Allergy
Clinical and Translational Allergy Immunology and Microbiology-Immunology
CiteScore
7.50
自引率
4.50%
发文量
117
审稿时长
12 weeks
期刊介绍: Clinical and Translational Allergy, one of several journals in the portfolio of the European Academy of Allergy and Clinical Immunology, provides a platform for the dissemination of allergy research and reviews, as well as EAACI position papers, task force reports and guidelines, amongst an international scientific audience. Clinical and Translational Allergy accepts clinical and translational research in the following areas and other related topics: asthma, rhinitis, rhinosinusitis, drug hypersensitivity, allergic conjunctivitis, allergic skin diseases, atopic eczema, urticaria, angioedema, venom hypersensitivity, anaphylaxis, food allergy, immunotherapy, immune modulators and biologics, animal models of allergic disease, immune mechanisms, or any other topic related to allergic disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信